Clene said it would submit additional CNM-Au8 clinical trial data and analysis to the FDA ahead of a planned meeting later this year.| ALS News Today
Clene submitted new data on CNM-Au8 to the FDA ahead of an upcoming meeting to discuss potential accelerated approval for the ALS therapy.| ALS News Today
After a year, patients given CNM-Au8 had improvements in vision and data suggested the therapy improved the health of brain nerve fibers.| Multiple Sclerosis News Today
The risk of death was nearly 60% lower in ALS patients given the experimental oral therapy CNM-Au8 than for an external placebo group, data show.| ALS News Today